Table II.
Comparison of clinicopathologic characteristics among the patient subgroups stratified by CA125 and AFP levels.
| Variables | Subgroup 1, n=95 | Subgroup 2, n=75 | Subgroup 3, n=57 | Subgroup 4, n=79 | P1 | P2 | P3 | P4 |
|---|---|---|---|---|---|---|---|---|
| Age, years, mean ± SD | 55.3±10.2 | 49.7±12.0 | 56.4±11.7 | 46.6±10.8 | 0.001a | 0.577a | 0.104a | <0.001a |
| Sex, male, n (%) | 79 (83.2%) | 68 (90.7%) | 51 (89.5%) | 63 (79.7%) | 0.155 | 0.284 | 0.057 | 0.129 |
| Hypertension, n (%) | 16 (16.8%) | 4 (5.3%) | 7 (12.3%) | 5 (6.3%) | 0.021 | 0.447 | – | 0.227 |
| Diabetes, n (%) | 19 (10.0%) | 12 (16.0%) | 16 (28.1%) | 21 (26.6%) | 0.502 | 0.253 | 0.110 | 0.847 |
| Platelet count, ×109/l | 177.6±62.2 | 178.7±66.8 | 178.0±74.2 | 221.0±93.8 | 0.912a | 0.970a | 0.002a | 0.005a |
| TBIL, µmol/l | 11.6 (9.4–15.4) | 11.9 (8.8–16.6) | 16.1 (11.6–21.8) | 12.8 (9.9–20.8) | 0.787b | 0.001b | 0.097b | 0.083b |
| ALT, IU/l | 40 (25–84) | 66 (36–114) | 49 (29–94) | 58 (37–85) | 0.008b | 0.245b | 0.548b | 0.457b |
| AST, IU/l | 71 (31–145) | 87 (43–126) | 80 (41–119) | 84 (48–132) | 0.350b | 0.812b | 0.622b | 0.260b |
| PT, sec | 14.8±1.6 | 15±1.6 | 15.3±1.7 | 14.8±1.6 | 0.520a | 0.086a | 0.510a | 0.088a |
| HBV DNA IU/ml , n (%) | 0.971 | 0.085 | 0.078 | 0.266 | ||||
| ≤2,000 | 39 (41.1%) | 31 (41.3%) | 21 (36.8%) | 22 (27.8%) | ||||
| >2,000 | 56 (58.9%) | 44 (58.7%) | 36 (63.2%) | 57 (72.2%) | ||||
| Albumin, g/l | 39.3 (36.6–40.7) | 38.8 (36.5–42.0) | 36.4 (33.5–39.3) | 37.5 (33.3–40.4) | 0.651b | <0.001b | 0.006b | 0.225b |
| ASA, n (%) | 0.202 | 0.326 | 0.213 | 0.231 | ||||
| I | 60 (63.2%) | 47 (62.7%) | 30 (52.6%) | 52 (65.8%) | ||||
| II | 31 (32.6%) | 28 (37.3%) | 22 (38.6%) | 24 (30.4%) | ||||
| III | 4 (4.2%) | 0 | 5 (8.8%) | 3 (3.8%) | ||||
| Child-Pugh grade, n (%) | 0.293 | 0.424 | 0.084 | 0.917 | ||||
| A | 75 (78.9%) | 54 (72.0%) | 48 (84.2%) | 66 (83.5%) | ||||
| B | 20 (21.1%) | 21 (28.0%) | 9 (15.8%) | 13 (16.5%) | ||||
| Cirrhosis | 78 (82.1%) | 68 (90.7%) | 48 (84.2%) | 65 (82.3%) | 0.111 | 0.739 | 0.129 | 0.767 |
| Ascites | 23 (24.2%) | 16 (21.3%) | 17 (29.8%) | 24 (30.4%) | 0.658 | 0.447 | 0.201 | 0.944 |
| TNM stage, n (%) | 0.027 | 0.162 | 0.007 | 0.005 | ||||
| I | 57 (60.0%) | 40 (53.3%) | 30 (52.7%) | 25 (31.6%) | ||||
| II | 22 (23.2%) | 10 (13.3%) | 10 (17.5%) | 8 (10.2%) | ||||
| III | 16 (16.8%) | 25 (33.3%) | 17 (29.8%) | 46 (58.2%) | ||||
| Tumor diameter, cm | 5.5±3.4 | 6.2±3.8 | 6.2±4.0 | 8.9±4.4 | 0.247 | 0.302 | <0.001 | <0.001 |
| Tumor number, n (%) | 0.010 | 0.464 | 0.004 | 0.289 | ||||
| Solitary | 70 (73.7%) | 67 (89.3%) | 45 (78.9%) | 56 (70.9%) | ||||
| Multiple | 25 (26.3%) | 8 (10.7%) | 12 (21.1%) | 23 (29.1%) | ||||
| Venous invasion, n (%) | 27 (28.4%) | 28 (37.3%) | 18 (31.6%) | 39 (49.4%) | 0.217 | 0.680 | 0.132 | 0.038 |
| Tumor differentiation, n (%) | 0.083 | 0.945 | 0.185 | 0.004 | ||||
| Well differentiated | 16 (16.8%) | 5 (6.7%) | 9 (15.8%) | 1 (1.3%) | ||||
| Moderately differentiated | 73 (76.8%) | 67 (89.3%) | 45 (78.9%) | 73 (92.4%) | ||||
| Poorly differentiated | 6 (6.3) | 3 (4.0%) | 3 (5.3%) | 5 (6.3) | ||||
| Intraoperative blood loss | 400 (200–700) | 400 (200–900) | 400 (200–1,000) | 600 (300–1,200) | 0.308b | 0.906b | 0.045b | 0.020b |
| Intraoperative | 24 (25.3%) | 29 (38.7%) | 22 (38.6%) | 43 (54.4%) | 0.061 | 0.083 | 0.050 | 0.068 |
| Surgery time transfusion, n (%) | 180 (135–210) | 180 (140–202) | 180 (125–194) | 180 (150–240) | 0.786b | 0.825b | 0.069b | 0.034b |
| TACE, n (%) | 0.009 | 0.009 | 0.210 | 0.148 | ||||
| ≤3 | 75 (78.9%) | 70 (93.3%) | 54 (94.7%) | 69 (87.3%) | ||||
| >3 | 20 (21.1%) | 5 (6.7%) | 3 (5.3%) | 10 (12.7%) |
Student's t-test
Mann-Whitney test. All other data were compared by the χ2 test. Subgroup 1, preoperative serum CA125 ≤15 U/ml and preoperative serum AFP ≤100 ng/ml; subgroup 2, preoperative serum CA125 ≤15 U/ml and preoperative serum AFP >100 ng/ml; subgroup 3, preoperative serum CA125 >15 U/ml and preoperative serum AFP ≤100 ng/ml; subgroup 4, preoperative serum CA125 >15 U/ml and preoperative serum AFP >100 ng/ml. P1, P-value of subgroup 1 vs. 2; P2, P-value of subgroup 1 vs. 3; P3, P-value of subgroup 2 vs. 4; P4, P-value of subgroup 3 vs. 4. CA125, cancer antigen 125; HBV, hepatitis B virus; ASA, American Society of Anesthesiologists; TNM, Tumor-Node-Metastasis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; TBIL, serum total bilirubin; AFP, α-fetoprotein; TACE, transcatheter arterial chemoembolization; ALB, serum albumin.